Zymeworks Inc (ZYME) Stock Price, Quote & News

Company Profile

Zymeworks Inc., a biotechnology company, develops biotherapeutics for the treatment of cancer, inflammation, and autoimmune diseases. The company's platforms include Azymetric multispecific antibody platform; Drug Conjugate platform that includes a suite of proprietary cytotoxins comprising topoisomerase and microtubulin inhibiting toxins, stable linkers, and conjugation technologies; EFECT platform, which consists of a set of modifications to the Fc region of antibodies; and ProTECT, a tumor-sp...

Industry: Biotechnology

Sector: Healthcare

Phone: 302 274 8744

Website: www.zymeworks.com

Address:

108 Patriot Drive, Suite A, Middletown, United States

Nickhzap May. 11 at 5:57 PM

$ZYME perfect time for you to buy! But if you like losing money you can always try and short. Just trying to help

0 · Reply

BuyingSheep May. 11 at 6:34 AM

$ZYME the selloff continues PM. Only a 🤡 believes this could recover.

0 · Reply

BuyingSheep May. 10 at 6:40 AM

$ZYME https://x.com/mr_derivatives/status/2053348526940475520?s=46&t=aY8FhnMFrLc8t1_0WkvgLw Imagine how this turd 💩 will plummet once we see the bubble burst. 🥰 Generational wealth being made.

1 · Reply

MarketBeat May. 9 at 9:06 AM

Zymeworks Q1 Earnings Call Highlights $ZYME https://www.marketbeat.com/instant-alerts/zymeworks-q1-earnings-call-highlights-2026-05-09/

0 · Reply

maplelakeduckslayer May. 9 at 3:20 AM

$ZYME https://youtu.be/MucEHKrbfgA?si=EEGaGVvS_e2gRfbr

0 · Reply

Tjcmd May. 8 at 11:57 PM

$ZYME FYI…

2 · Reply

JFais May. 8 at 8:21 PM

$ZYME (NP) Interesting on today's gap down at $1.4B EV Repurchased 3.9M shares since Nov $403M of cash + $440M anticipated regulatory milestones = runway beyond 2028 Interesting optionality between BiC FRα & triumvirate of pan-RASi ADCs (PTK7, Ly6E and CLDN18.2 co-targets)

2 · Reply

BuyingSheep May. 8 at 7:35 PM

$ZYME misssed that one https://www.fiercebiotech.com/biotech/bms-calls-time-zymeworks-collab-ending-work-phase-1-stage-cancer-bispecific

1 · Reply

ScoobieDoo May. 8 at 3:58 PM

$ZYME just averaged up to a lofty 11.75

1 · Reply

BuyingSheep May. 8 at 3:35 PM

$ZYME 🤡

0 · Reply

Zymeworks Announces Participation in Upcoming Investor Conferences

2026-05-07T21:19:18.000Z - 6 days ago

Zymeworks reports Q1 EPS (59c), consensus (10c)

May 7, 2026, 4:30 PM EDT - 6 days ago

Zymeworks Earnings Call Transcript: Q1 2026

May 7, 2026, 4:05 PM EDT - 6 days ago

Zymeworks Provides Corporate Update and Reports First Quarter 2026 Financial Results

2026-04-21T21:35:17.000Z - 22 days ago

Zymeworks reports results from dose-escalation part of Phase 1 study for ZW191

Apr 21, 2026, 5:30 PM EDT - 22 days ago

Zymeworks Presents New Phase 1 Data for ZW191, a Folate Receptor Alpha-Targeting ADC at AACR Annual Meeting 2026

Apr 21, 2026, 9:30 AM EDT - 22 days ago

Zymeworks Transcript: 2026 Bloom Burton & Co. Healthcare Investor Conference

Apr 17, 2026, 3:00 PM EDT - 26 days ago

Zymeworks Presents New Preclinical Data at AACR 2026 Highlighting Broad Antibody-Drug Conjugate Programs Including Novel RAS-Targeting Platform

Apr 16, 2026, 6:00 AM EDT - 27 days ago

Zymeworks to Report First Quarter 2026 Financial Results and Host Conference Call on May 7, 2026

Apr 15, 2026, 10:15 AM EDT - 4 weeks ago

Zymeworks Transcript: 25th Annual Needham Virtual Healthcare Conference

2026-04-09T10:11:05.000Z - 4 weeks ago

Zymeworks appoints new Head of R&D and Chief Business Officer

Apr 9, 2026, 6:00 AM EDT - 4 weeks ago

Zymeworks Announces Additional Leadership Appointments to Advance Next Phase of Growth

2026-04-01T10:06:59.000Z - 6 weeks ago

Zymeworks appoints Kristin Stafford as CFO

NVCR

Apr 1, 2026, 6:00 AM EDT - 6 weeks ago

Zymeworks Appoints Kristin Stafford as Chief Financial Officer

2026-03-30T10:06:54.000Z - 6 weeks ago

Zymeworks receives FDA Fast Track Designation for ZW191

2026-03-30T10:05:07.000Z - 6 weeks ago

Zymeworks announces Fast Track designation for ZW191 by FDA

Mar 30, 2026, 6:00 AM EDT - 6 weeks ago

Zymeworks Receives U.S. FDA Fast Track Designation for ZW191, an FRα-Targeting Antibody-Drug Conjugate

Mar 24, 2026, 6:00 AM EDT - 7 weeks ago

Zymeworks Announces Participation in Upcoming Investor Conferences

2026-03-18T11:51:22.000Z - 2 months ago

Zymework’ partner Jazz to present on Ziihera at 2026 AACR Annual Meeting

JAZZ

Mar 18, 2026, 7:46 AM EDT - 2 months ago

Zymeworks Announces Presentations for Ziihera® (zanidatamab-hrii) at 2026 AACR Annual Meeting

Mar 17, 2026, 5:02 PM EDT - 2 months ago

Zymeworks to Present Clinical and Preclinical Data on ADC Programs Including Novel RAS ADC Platform at AACR Annual Meeting

Mar 11, 2026, 10:10 AM EDT - 2 months ago

Zymeworks Transcript: The Citizens Life Sciences Conference 2026

Mar 9, 2026, 3:00 PM EDT - 2 months ago

Zymeworks Transcript: Leerink Global Healthcare Conference 2026

2026-03-09T12:10:52.000Z - 2 months ago

Zymeworks price target raised to $48 from $33 at Evercore ISI

RPRX

2026-03-06T11:22:16.000Z - 2 months ago

Zymeworks price target raised to $46 from $32 at H.C. Wainwright

2026-03-03T12:25:37.000Z - 2 months ago

Zymeworks price target raised to $47 from $40 at Stifel

Mar 2, 2026, 2:30 PM EST - 2 months ago

Zymeworks Transcript: TD Cowen 46th Annual Health Care Conference

Mar 2, 2026, 8:30 AM EST - 2 months ago

Zymeworks Earnings Call Transcript: Q4 2025

2026-03-02T11:15:10.000Z - 2 months ago

Zymeworks, Royalty Pharma enter $250M royalty-backed note financing

JAZZ ONC RPRX

2026-03-02T11:10:50.000Z - 2 months ago

Zymeworks reports Q4 EPS (55c) vs. (31c) last year

Mar 2, 2026, 6:01 AM EST - 2 months ago

Zymeworks and Royalty Pharma Enter into $250 Million Royalty-Backed Note Financing

Mar 2, 2026, 6:00 AM EST - 2 months ago

Zymeworks Provides Corporate Update and Reports Fourth Quarter and Full Year 2025 Financial Results

Feb 12, 2026, 6:00 AM EST - 3 months ago

Zymeworks To Report Fourth Quarter and Full Year 2025 Financial Results and Host Conference Call on March 2, 2026

Jan 14, 2026, 6:00 PM EST - 4 months ago

Zymeworks Transcript: 44th Annual J.P. Morgan Healthcare Conference

2026-01-12T11:31:44.000Z - 4 months ago

Zymeworks announces executive changes

Jan 12, 2026, 6:00 AM EST - 4 months ago

Zymeworks Announces Leadership Appointments and Transitions to Align with Evolution of Corporate Strategy

2026-01-12T00:25:31.000Z - 4 months ago

Zymeworks outlines priorities, outlook for 2026

Jan 11, 2026, 6:00 PM EST - 4 months ago

Zymeworks Outlines Strategic Priorities and Outlook for 2026

2026-01-06T18:45:54.000Z - 4 months ago

Zymeworks touts ‘unprecedented’ results from HERIZON-GEA-01 trial

JAZZ ONC

Jan 6, 2026, 1:34 PM EST - 4 months ago

Ziihera® (zanidatamab-hrii) Combinations Achieve Unprecedented Results in First-Line HER2+ Locally Advanced or Metastatic GEA including more than Two Years Median Overall Survival Benefit

2025-12-17T11:21:22.000Z - 5 months ago

Zymeworks initiated with a Buy at Truist

Dec 2, 2025, 4:05 PM EST - 5 months ago

Zymeworks Announces Participation in Upcoming Conferences

Dec 2, 2025, 10:00 AM EST - 5 months ago

Zymeworks Transcript: Evercore ISI 8th Annual HealthCONx Conference

Nov 18, 2025, 8:30 AM EST - 6 months ago

Zymeworks Transcript: Investor Update

Nov 18, 2025, 1:01 AM EST - 6 months ago

Zymeworks Appoints Scott Platshon as Acting Chief Investment Officer

Nov 18, 2025, 1:00 AM EST - 6 months ago

Zymeworks Announces Strategic Initiative to Optimize Value of Licensed Products by Building a Diversified Portfolio of Revenue-Generating Assets

Nov 17, 2025, 8:10 AM EST - 6 months ago

Jazz Pharmaceuticals and Zymeworks Report Positive Cancer Treatment Results. The Stocks Soar.

JAZZ

Nov 17, 2025, 6:00 AM EST - 6 months ago

Zymeworks Announces Positive HERIZON-GEA-01 Phase 3 Results Supporting Ziihera® (zanidatamab-hrii) as HER2-Targeted Agent-of-Choice and New Standard of Care in First-Line HER2-Positive Locally Advanced or Metastatic Gastroesophageal Adenocarcinoma

Nov 6, 2025, 4:30 PM EST - 6 months ago

Zymeworks Earnings Call Transcript: Q3 2025

Nov 6, 2025, 4:05 PM EST - 6 months ago

Zymeworks Provides Corporate Update and Reports Third Quarter 2025 Financial Results

Oct 23, 2025, 3:30 PM EDT - 7 months ago

Zymeworks Transcript: Study Result

Oct 23, 2025, 12:30 PM EDT - 7 months ago

Zymeworks Presents Initial Clinical Data from the Phase 1 trial of ZW191, an Antibody-Drug Conjugate Targeting Folate Receptor-⍺ at AACR-NCI-EORTC Conference

Oct 16, 2025, 6:00 AM EDT - 7 months ago

Zymeworks to Report Third Quarter 2025 Financial Results and Host Conference Call on November 6, 2025

Oct 13, 2025, 4:00 PM EDT - 7 months ago

Zymeworks to Present Clinical Data from the Phase 1 trial of ZW191, an Antibody-Drug Conjugate Targeting Folate Receptor-⍺, at AACR-NCI-EORTC International Conference

Oct 9, 2025, 8:30 AM EDT - 7 months ago

InMed Pharmaceuticals Appoints Mr. Neil Klompas to It's Board of Directors

INM

Oct 9, 2025, 6:00 AM EDT - 7 months ago

Zymeworks Appoints Dr. Adam Schayowitz as Acting Chief Development Officer

Sep 4, 2025, 4:30 PM EDT - 8 months ago

Zymeworks Transcript: Wells Fargo 20th Annual Healthcare Conference 2025

Sep 2, 2025, 6:18 AM EDT - 9 months ago

Zymeworks halts development of cancer drug after trial setback

Sep 2, 2025, 6:00 AM EDT - 9 months ago

Zymeworks Announces Decision to Discontinue Clinical Development of ZW171, a Mesothelin-directed T cell Engager

Aug 11, 2025, 6:00 AM EDT - 9 months ago

Zymeworks Strengthens Board of Directors with Appointments of Greg Ciongoli and Robert E. Landry

Aug 7, 2025, 4:30 PM EDT - 9 months ago

Zymeworks Earnings Call Transcript: Q2 2025

Aug 7, 2025, 4:05 PM EDT - 9 months ago

Zymeworks Provides Corporate Update and Reports Second Quarter 2025 Financial Results

Jul 28, 2025, 6:00 AM EDT - 10 months ago

Zymeworks Announces FDA Clearance of Investigational New Drug Application for ZW251, a Novel Glypican 3-Targeted Topoisomerase 1 Inhibitor Antibody-Drug Conjugate

Jul 17, 2025, 6:00 AM EDT - 10 months ago

Zymeworks to Report Second Quarter 2025 Financial Results and Host Conference Call on August 7, 2025

Jun 11, 2025, 2:00 PM EDT - 1 year ago

Zymeworks Transcript: Goldman Sachs 46th Annual Global Healthcare Conference 2025

May 30, 2025, 6:00 AM EDT - 1 year ago

Zymeworks Announces NMPA Approval of Zanidatamab in China for Adults with Previously Treated, Unresectable or Metastatic HER2-high expression (IHC3+) Biliary Tract Cancer

May 22, 2025, 5:00 PM EDT - 1 year ago

Zymeworks Announces Presentations Highlighting Breadth of Oncology Portfolio at Upcoming Medical Conferences

May 19, 2025, 4:15 PM EDT - 1 year ago

Zymeworks Presents Preclinical Data on ZW1528 at the American Thoracic Society International Conference

May 8, 2025, 4:30 PM EDT - 1 year ago

Zymeworks Earnings Call Transcript: Q1 2025

May 8, 2025, 4:05 PM EDT - 1 year ago

Zymeworks Provides Corporate Update and Reports First Quarter 2025 Financial Results

Apr 25, 2025, 1:00 PM EDT - 1 year ago

Zymeworks Presents New Data from Multiple Development Programs at 2025 AACR Annual Meeting

Apr 21, 2025, 6:00 AM EDT - 1 year ago

Zymeworks Appoints Dr. Sabeen Mekan as Senior Vice President, Clinical Development

Apr 17, 2025, 6:00 AM EDT - 1 year ago

Zymeworks to Report First Quarter 2025 Financial Results and Host Conference Call on May 8, 2025

Mar 25, 2025, 4:30 PM EDT - 1 year ago

Zymeworks to Present Preclinical Data on T cell Engager and Antibody-Drug Conjugate Platforms in Six Posters at AACR Annual Meeting

Mar 5, 2025, 4:30 PM EST - 1 year ago

Zymeworks Earnings Call Transcript: Q4 2024

Mar 5, 2025, 4:05 PM EST - 1 year ago

Zymeworks Provides Corporate Update and Reports Fourth Quarter and Full Year 2024 Financial Results

Feb 26, 2025, 6:00 AM EST - 1 year ago

Zymeworks Announces Achievement of $14 Million Milestone from GSK Collaboration

Feb 20, 2025, 2:00 PM EST - 1 year ago

Zymeworks Transcript: Citi's 2025 Virtual Oncology Leadership Summit

Feb 18, 2025, 6:00 AM EST - 1 year ago

Zymeworks Announces Appointment of Oleg Nodelman to Board of Directors

Feb 13, 2025, 6:00 AM EST - 1 year ago

Zymeworks To Report Fourth Quarter and Full Year 2024 Financial Results and Host Conference Call on March 5, 2025

Jan 16, 2025, 11:15 AM EST - 1 year ago

Zymeworks Transcript: 43rd Annual J.P. Morgan Healthcare Conference 2025

Jan 8, 2025, 4:05 PM EST - 1 year ago

Zymeworks Outlines Strategic Priorities and Outlook for 2025 and 2026

Dec 12, 2024, 8:30 AM EST - 1 year ago

Zymeworks Transcript: Status Update

Nov 21, 2024, 6:00 AM EST - 1 year ago

FDA Grants U.S. Approval of Ziihera® (zanidatamab-hrii) for the Treatment of Adults with Previously Treated, Unresectable or Metastatic HER2-positive (IHC 3+) Biliary Tract Cancer (BTC)

Nov 5, 2024, 6:00 AM EST - 1 year ago

Zymeworks Announces First Patient Dosed in Phase 1 Clinical Trial Evaluating ZW191 in Folate Receptor-⍺ Expressing Advanced Solid Tumors

Oct 31, 2024, 4:30 PM EDT - 1 year ago

Zymeworks Earnings Call Transcript: Q3 2024

Oct 25, 2024, 6:00 AM EDT - 1 year ago

Zymeworks Presents New Preclinical Data on Antibody-Drug Conjugate Programs at EORTC-NCI-AACR Conference

Nickhzap May. 11 at 5:57 PM

$ZYME perfect time for you to buy! But if you like losing money you can always try and short. Just trying to help

0 · Reply

BuyingSheep May. 11 at 6:34 AM

$ZYME the selloff continues PM. Only a 🤡 believes this could recover.

0 · Reply

BuyingSheep May. 10 at 6:40 AM

$ZYME https://x.com/mr_derivatives/status/2053348526940475520?s=46&t=aY8FhnMFrLc8t1_0WkvgLw Imagine how this turd 💩 will plummet once we see the bubble burst. 🥰 Generational wealth being made.

1 · Reply

MarketBeat May. 9 at 9:06 AM

Zymeworks Q1 Earnings Call Highlights $ZYME https://www.marketbeat.com/instant-alerts/zymeworks-q1-earnings-call-highlights-2026-05-09/

0 · Reply

maplelakeduckslayer May. 9 at 3:20 AM

$ZYME https://youtu.be/MucEHKrbfgA?si=EEGaGVvS_e2gRfbr

0 · Reply

Tjcmd May. 8 at 11:57 PM

$ZYME FYI…

2 · Reply

JFais May. 8 at 8:21 PM

2 · Reply

BuyingSheep May. 8 at 7:35 PM

$ZYME misssed that one https://www.fiercebiotech.com/biotech/bms-calls-time-zymeworks-collab-ending-work-phase-1-stage-cancer-bispecific

1 · Reply

ScoobieDoo May. 8 at 3:58 PM

$ZYME just averaged up to a lofty 11.75

1 · Reply

BuyingSheep May. 8 at 3:35 PM

$ZYME 🤡

0 · Reply

maplelakeduckslayer May. 8 at 1:38 PM

$ZYME took some more on the gfs and mine roths...have a lot of cash available again after getting out of my BAND swing

0 · Reply

BuyingSheep May. 8 at 1:35 PM

$ZYME jeeez, what a dump 🤩💲💲💸💸

1 · Reply

StarshipBlooper May. 8 at 12:04 AM

$ZYME the heck?

0 · Reply

BuyingSheep May. 7 at 8:25 PM

$ZYME Party on! 😂

1 · Reply

StocktwitsEarnings May. 7 at 8:21 PM

$ZYME Q1 '26 Earnings Results & Recap • Reported GAAP EPS of -$0.59 down -96.67% YoY • Reported revenue of $2.41M down -91.12% YoY • Zymeworks expects adjusted gross operating expenses (non-GAAP) in 2026 to be approximately 20% lower than the $170.5M reported in 2025, reflecting disciplined investment.

0 · Reply

BuyingSheep May. 7 at 4:02 PM

$ZYME the dump continues 🤡

0 · Reply

Boris_Badenov May. 6 at 12:31 PM

$ZYME Jazz reported $13 million in Ziihera sales for 1Q26, little over 50% growth from previous quarter. Zyme jazz mgmt stated they’re ready to launch on approval for GEA. Data for the Phase 3 breastcancer study expected late 2027/early 2028. Early innings for Zyme’s revenue growth for this drug.

0 · Reply

Night_Owl_Biotech May. 4 at 1:54 AM

$JAZZ v $GMAB valuation related data points. JAZZ trades at 75-80% of GMAB's valuation yet is expected to generate 90% of GMAB's 5-year forecast. Put simpler, JAZZ trades at 0.60X 5-year analyst consensus while GMAB trades at 0.70X. GMAB's FY25 gross margin was 2% higher than JAZZ & GMAB is digesting its MRUS acquisition. We're curious if $ZYME investors expect a JAZZ buyout at this point? $XBI $IBB

0 · Reply

BuyingSheep May. 1 at 6:20 PM

$ZYME wow, look at that. Straight line down.

1 · Reply

maplelakeduckslayer Apr. 27 at 2:07 PM

$ZYME FDA accepted Jazzs application for zani in gea, pdufa date August 25

0 · Reply

NyseDayTrader Apr. 27 at 1:49 PM

$ZYME

0 · Reply

mostbullish Apr. 25 at 8:47 PM

$ZYME ZW191 AACR update: The breakout 📈speaks for itself. Float is verysmall on this one. ZW191 AACR update: • 61% cORR in platinum-resistant ovarian cancer (6.4–9.6 mg/kg) • Early Elahere ~30% ORR pooled / 47% selected subgroup → ZW191 showing stronger early efficacy signal • 100% disease control in optimized ovarian/endometrial cohorts • 1.4 month time to response = fast activity • 6.4 mg/kg emerging as likely sweet spot • Ongoing optimization trial now key catalyst: goal is preserve efficacy while lowering AEs • If durability holds + safety improves, ZW191 could become a serious next-gen FRα challenger I’m a bagholder and wont be selling :-) $ZYME #biotech #oncology

1 · Reply

Market Cap	1.75B
Revenue (ttm)	105.97M
Net Income (ttm)	-81.13M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	24.74
Profit Margin	-76.56%
Debt to Equity Ratio	0.00

Volume	646,700
Avg Vol	680,996
Day's Range	N/A - N/A
Shares Out	73.02M
Stochastic %K	11%
Beta	1.20
Analysts	Strong Sell
Price Target	$40.15